Philadelphia, PA (January 27, 2020) – Oncoceutics announced that the National Brain Tumor Society (NBTS) has committed to providing more than $200,000 in funding, with the potential for multiple years, to support a Phase II clinical trial of ONC201, the first imipridone dopamine receptor D2 antagonist (DRD2), in a molecular subset of high grade gliomas.
Philadelphia, PA (November 20, 2019) – Oncoceutics, Inc. announced that new data will be presented on the efficacy and mechanism of action of imipridones ONC201 and ONC206 at the 24nd Annual Scientific Meeting of the Society of Neuro-Oncology, to be held November 20th-24th in Phoenix, Arizona. These data will highlight exciting findings that have emerged
Philadelphia, PA (Nov. 19, 2019) – Oncoceutics, Inc. announced a publication in the journal Nature Communications demonstrating selective antagonism of the G-protein coupled receptor (GPCR) dopamine receptor D2 (DRD2) by Oncoceutics’ lead candidate imipridone, ONC201. ONC201 was found to specifically bind and antagonize DRD2, and its functionally redundant family member DRD3, without affecting other dopamine
Philadelphia, PA (November 13, 2019) – Oncoceutics, Inc. announced that results from the second and third cohort of the Phase II trial for patients with recurrent glioblastoma treated with the company’s lead imipridone, ONC201, were recently published in the journal Neuro-Oncology. This manuscript represents the third publication among a series of reports demonstrating durable radiographic
Business Development